Biovica International Past Earnings Performance
Past criteria checks 0/6
Biovica International's earnings have been declining at an average annual rate of -38.1%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 16.3% per year.
Key information
-38.1%
Earnings growth rate
-22.9%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | -16.3% |
| Return on equity | -90.4% |
| Net Margin | -1,765.8% |
| Next Earnings Update | 18 Jun 2024 |
Recent past performance updates
Recent updates
Is Biovica International (STO:BIOVIC B) In A Good Position To Deliver On Growth Plans?
Jul 18
Here's Why We're Watching Biovica International's (STO:BIOVIC B) Cash Burn Situation
Dec 02Here's Why We're Not Too Worried About Biovica International's (STO:BIOVIC B) Cash Burn Situation
Aug 02Here's Why We're Not At All Concerned With Biovica International's (STO:BIOVIC B) Cash Burn Situation
Feb 17A Look At The Intrinsic Value Of Biovica International AB (publ) (STO:BIOVIC B)
Jan 19Companies Like Biovica International (STO:BIOVIC B) Can Afford To Invest In Growth
Nov 11We Think Biovica International (STO:BIOVIC B) Can Easily Afford To Drive Business Growth
Aug 06We're Not Worried About Biovica International's (STO:BIOVIC B) Cash Burn
Mar 20Who Has Been Buying Biovica International AB (publ) (STO:BIOVIC B) Shares?
Feb 22What Kind Of Shareholders Hold The Majority In Biovica International AB (publ)'s (STO:BIOVIC B) Shares?
Jan 26The Biovica International (STO:BIOVIC B) Share Price Has Soared 349%, Delighting Many Shareholders
Dec 31
Here's Why We're Not At All Concerned With Biovica International's (STO:BIOVIC B) Cash Burn Situation
Dec 05Revenue & Expenses BreakdownBeta
How Biovica International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jan 24 | 7 | -123 | 120 | 0 |
| 31 Oct 23 | 7 | -124 | 122 | 0 |
| 31 Jul 23 | 6 | -122 | 120 | 0 |
| 30 Apr 23 | 5 | -110 | 107 | 0 |
| 31 Jan 23 | 6 | -92 | 89 | 0 |
| 31 Oct 22 | 5 | -78 | 76 | 0 |
| 31 Jul 22 | 5 | -69 | 67 | 0 |
| 30 Apr 22 | 5 | -60 | 59 | 0 |
| 31 Jan 22 | 3 | -53 | 52 | 0 |
| 31 Oct 21 | 4 | -50 | 48 | 0 |
| 31 Jul 21 | 7 | -43 | 45 | 0 |
| 30 Apr 21 | 7 | -39 | 43 | 0 |
| 31 Jan 21 | 9 | -38 | 42 | 0 |
| 31 Oct 20 | 10 | -35 | 40 | 0 |
| 31 Jul 20 | 10 | -33 | 38 | 0 |
| 30 Apr 20 | 10 | -30 | 35 | 0 |
| 31 Jan 20 | 12 | -25 | 33 | 0 |
| 31 Oct 19 | 11 | -24 | 32 | 0 |
| 31 Jul 19 | 10 | -24 | 30 | 0 |
| 30 Apr 19 | 10 | -22 | 28 | 0 |
| 31 Jan 19 | 10 | -20 | 25 | 0 |
| 31 Oct 18 | 9 | -20 | 25 | 0 |
| 31 Jul 18 | 9 | -19 | 24 | 0 |
| 30 Apr 18 | 10 | -18 | 24 | 0 |
| 31 Jan 18 | 9 | -20 | 25 | 0 |
| 31 Oct 17 | 9 | -18 | 23 | 0 |
| 31 Jul 17 | 8 | -16 | 21 | 0 |
| 30 Apr 17 | 6 | -15 | 19 | 0 |
| 31 Jan 17 | 6 | -11 | 15 | 0 |
| 31 Oct 16 | 6 | -9 | 14 | 0 |
| 31 Jul 16 | 7 | -7 | 13 | 0 |
| 30 Apr 16 | 7 | -6 | 12 | 0 |
| 30 Apr 15 | 4 | -7 | 10 | 0 |
| 30 Apr 14 | 4 | -5 | 8 | 0 |
Quality Earnings: BIOVIC B is currently unprofitable.
Growing Profit Margin: BIOVIC B is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIOVIC B is unprofitable, and losses have increased over the past 5 years at a rate of 38.1% per year.
Accelerating Growth: Unable to compare BIOVIC B's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIOVIC B is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: BIOVIC B has a negative Return on Equity (-90.42%), as it is currently unprofitable.